These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34709352)

  • 1. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
    Nadelmann ER; Yeh JE; Chen ST
    JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
    Du Y; Wu W; Chen M; Dong Z; Wang F
    JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INDIVIDUAL ARTICLE: NECOM 4: Algorithm Integrating Skincare for the Management of Immunotherapy-Related Cutaneous Adverse Events for Cancer Patients and Survivors.
    Girnita A; Fournier C; Bjerring P; Kauppi S; Andriessen A; Lynde C; Sauder M; Stensvold A
    J Drugs Dermatol; 2024 Aug; 23(8):85411s3-85411s10. PubMed ID: 39093665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
    Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
    JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
    Curkovic NB; Bai K; Ye F; Johnson DB
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
    Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
    Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
    Storgard R; Markova A
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
    Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
    J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    medRxiv; 2023 Jan; ():. PubMed ID: 36711758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events.
    Deutsch A; Lacouture M; Andriessen A; Choi JN; Ho AY; McLellan BN; Mitchell E; Leventhal JS
    J Drugs Dermatol; 2023 Nov; 22(11):SF389716s3-SF389716s10. PubMed ID: 37943279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity - a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital.
    Juan-Carpena G; Martínez-Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
    Clin Exp Dermatol; 2024 Aug; 49(9):991-1001. PubMed ID: 38372424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review.
    Caravan S; Lopez CM; Yeh JE
    JAMA Dermatol; 2024 Feb; 160(2):210-217. PubMed ID: 38198130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
    Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
    Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.